In a small study, the bioavailability of selegiline was markedly higher (
mean of about 20-fold) in women taking combined oral
contraceptives than in those not taking
contraceptives.
One UK manufacturer of selegiline advises caution on the concurrent use of
contraceptives, and the other suggests that concurrent use should be avoided.